Marc Navre

Marc Navre has over 30 years of experience in the biotechnology and pharmaceutical industry. Marc is currently serving as the Sr. Vice President of Biology at Structure Therapeutics since July 2021.

In 2012, Marc founded Wemberly Scientific, Inc., a company that provides consulting services in the fields of drug discovery and discovery informatics. Marc held various roles within the company, including Consulting Sr. VP of Research at a public drug discovery company, Consulting Biologist and Project Team Leader at a private biotechnology company, Drug Discovery & Informatics Consultant at a cloud-based informatics company, and implementing a search engine for Research and Development documents at a private biotech company.

From 2017 to 2021, Marc served as the CEO and Co-founder of Facile Therapeutics, Inc., a company focused on developing a small molecule to treat recurring infections caused by C. diff.

Prior to that, they worked at Ardelyx as the Vice President of Biology and Pharmacology from 2008 to 2012. Marc played a crucial role in building and managing the company's biology platform and was involved in the development of the non-systemic drug Tenapanor.

Marc also served as the Vice President of Drug Discovery at Catalyst Biosciences from 2006 to 2008, where they managed departments related to Molecular Biology, Discovery Biology, Bioanalytical Chemistry, and Informatics. Marc was instrumental in delivering Catalyst's first Development Candidate, Marzeptacog alfa.

From 2001 to 2006, Marc was the Vice President of Biology at Takeda San Diego, Inc. Marc led a department responsible for enzyme and cellular pharmacology, medium-throughput screening, automation, and compound management. Marc also contributed to the discovery of Alogliptin, a selective inhibitor of Dipeptidyl Peptidase IV.

Earlier in their career, Marc worked at Affymax Research Institute as the Director of the Titanium Research Unit. Marc was responsible for medicinal and high-throughput chemistry, assay development, and scientific computing. Marc also played a key role in the development and implementation of the Affymax Comprehensive Systems Based Research (CSBR) program.

Before that, Marc worked as a Staff Scientist at Syntex.

Overall, Marc Navre has a diverse and extensive work experience in different leadership and scientific roles within the biotechnology and pharmaceutical industry.

Marc Navre attended the University of California, Berkeley from 1979 to 1984. No degree or field of study information is provided for this education. There is no further information about their education history, although it is mentioned that they also have some association with Stanford University.